Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, Radisky ES.

Oncotarget. 2015 Nov 3;6(34):35737-54. doi: 10.18632/oncotarget.5927.

2.

SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression.

Tiwari R, Pandey SK, Goel S, Bhatia V, Shukla S, Jing X, Dhanasekaran SM, Ateeq B.

Oncogenesis. 2015 Aug 10;4:e162. doi: 10.1038/oncsis.2015.23.

3.

Inflammation to cancer: The molecular biology in the pancreas (Review).

Ling S, Feng T, Jia K, Tian Y, Li Y.

Oncol Lett. 2014 Jun;7(6):1747-1754. Epub 2014 Mar 28.

4.

Application of an electrochemical immunosensor with a MWCNT/PDAA modified electrode for detection of serum trypsin.

Yi Q, Liu Q, Gao F, Chen Q, Wang G.

Sensors (Basel). 2014 Jun 10;14(6):10203-12. doi: 10.3390/s140610203.

5.

Human colonic crypts in culture: segregation of immunochemical markers in normal versus adenoma-derived.

Dame MK, Jiang Y, Appelman HD, Copley KD, McClintock SD, Aslam MN, Attili D, Elmunzer BJ, Brenner DE, Varani J, Turgeon DK.

Lab Invest. 2014 Feb;94(2):222-34. doi: 10.1038/labinvest.2013.145. Epub 2013 Dec 23.

6.

Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.

Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot FR, Hebbar M, Fan F, Ellis LM, Formstecher P, Van Seuningen I, Gespach C, Polakowska R, Huet G.

Clin Cancer Res. 2014 Feb 15;20(4):837-46. doi: 10.1158/1078-0432.CCR-13-1854. Epub 2013 Dec 9.

7.

Role of Intrapancreatic SPINK1/Spink3 Expression in the Development of Pancreatitis.

Ohmuraya M, Sugano A, Hirota M, Takaoka Y, Yamamura K.

Front Physiol. 2012 May 7;3:126. doi: 10.3389/fphys.2012.00126. eCollection 2012.

8.

Global alteration in gene expression profiles of deciduas from women with idiopathic recurrent pregnancy loss.

Krieg SA, Fan X, Hong Y, Sang QX, Giaccia A, Westphal LM, Lathi RB, Krieg AJ, Nayak NR.

Mol Hum Reprod. 2012 Sep;18(9):442-50. doi: 10.1093/molehr/gas017. Epub 2012 Apr 14.

9.

Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients.

Gaber A, Stene C, Hotakainen K, Nodin B, Palmquist I, Bjartell A, Stenman UH, Jeppsson B, Johnson LB, Jirström K.

Radiat Oncol. 2011 Aug 24;6:100. doi: 10.1186/1748-717X-6-100.

10.

Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer.

Soon WW, Miller LD, Black MA, Dalmasso C, Chan XB, Pang B, Ong CW, Salto-Tellez M, Desai KV, Liu ET.

EMBO Mol Med. 2011 Aug;3(8):451-64. doi: 10.1002/emmm.201100150. Epub 2011 Jun 8.

11.

Pancreatic secretory trypsin inhibitor: More than a trypsin inhibitor.

Wang GP, Xu CS.

World J Gastrointest Pathophysiol. 2010 Jun 15;1(2):85-90. doi: 10.4291/wjgp.v1.i2.85.

12.

Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development.

Stenman UH.

Asian J Androl. 2011 Jul;13(4):628-9. doi: 10.1038/aja.2011.45. Epub 2011 May 23. No abstract available.

13.

Therapeutic targeting of SPINK1-positive prostate cancer.

Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM.

Sci Transl Med. 2011 Mar 2;3(72):72ra17. doi: 10.1126/scitranslmed.3001498.

14.

Stromal microenvironment processes unveiled by biological component analysis of gene expression in xenograft tumor models.

Yang X, Lee Y, Huang Y, Chen JL, Xing RH, Lussier YA.

BMC Bioinformatics. 2010 Oct 28;11 Suppl 9:S11. doi: 10.1186/1471-2105-11-S9-S11.

15.

Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.

Gaber A, Nodin B, Hotakainen K, Nilsson E, Stenman UH, Bjartell A, Birgisson H, Jirström K.

BMC Cancer. 2010 Sep 17;10:498. doi: 10.1186/1471-2407-10-498.

16.

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS; Transatlantic Prostate Group.

Br J Cancer. 2010 Feb 16;102(4):678-84. doi: 10.1038/sj.bjc.6605554. Epub 2010 Jan 26.

17.

Human colon tissue in organ culture: preservation of normal and neoplastic characteristics.

Dame MK, Bhagavathula N, Mankey C, DaSilva M, Paruchuri T, Aslam MN, Varani J.

In Vitro Cell Dev Biol Anim. 2010 Feb;46(2):114-22. doi: 10.1007/s11626-009-9247-9.

18.

High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer.

Gaber A, Johansson M, Stenman UH, Hotakainen K, Pontén F, Glimelius B, Bjartell A, Jirström K, Birgisson H.

Br J Cancer. 2009 May 19;100(10):1540-8. doi: 10.1038/sj.bjc.6605047. Epub 2009 Apr 21.

Items per page

Supplemental Content

Write to the Help Desk